Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr 27:9:100027.
doi: 10.1016/j.iotech.2021.100027. eCollection 2021 Mar.

ESMO pays tribute to Professor José Baselga

S Peters  1 , J Tabernero  2 , A Cervantes  3 , S Banerjee  4 , R Giuliani  5 , F Lordick  6
Affiliations
Editorial

ESMO pays tribute to Professor José Baselga

S Peters et al. Immunooncol Technol. .
No abstract available

PubMed Disclaimer

References

    1. Baselga J. Creating a stronger front against cancer: ESMO and ECCO join forces. Ann Oncol. 2008;9:1367–1368. - PubMed
    1. Baselga J., Swain S.M. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10(6):489–491. - PubMed
    1. Baselga J., Cortés J., Im S.-A., et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–3761. - PubMed
    1. Piccart M., Hortobagyi G.N., Campone M., et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357–2362. - PMC - PubMed
    1. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. - PMC - PubMed

Publication types

LinkOut - more resources